•
LX
LXRX
Lexicon Pharmaceuticals, Inc.
polygonPHARMACEUTICAL PREPARATIONS
--
Price Chart
Market Cap
566.90M
Volume
5.01M
52W High
$1.77
52W Low
$0.28
Open
$1.55
Prev Close
$1.56
Day Range
1.52 - 1.77
About Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
Latest News
Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025
GlobeNewswire Inc.•Nov 8
Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes
GlobeNewswire Inc.•Sep 22
Lexicon to Present Patient-reported Data on Diabetic Peripheral Neuropathic Pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025)
GlobeNewswire Inc.•Jul 18
US Stocks Likely To Open Lower After 3-Day Fall: 'Equity Drawdown Probability Hasn't Peaked Yet,' Says Goldman Sachs Analyst
Benzinga•Mar 31
While Wall Street Panicked, These 3 Hidden Small-Caps Exploded Last Week — One Surging A Jaw-Dropping 60%
Benzinga•Mar 31
Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
GlobeNewswire Inc.•Mar 6
Lexicon Pharmaceuticals to Announce Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain
GlobeNewswire Inc.•Mar 2
George Medicines appoints Amy Carroll as Senior Vice President of Medical Affairs
GlobeNewswire Inc.•Feb 3